Free Republic

Merck announced on Thursday that the United Kingdom conditionally authorized the use of its antiviral COVID-19 pill, molnupiravir. The pharmaceutical company said that molnupiravir, developed with Ridgeback Biotherapeutics, had been authorized for use in Britain to treat mild to moderate cases of COVID-19 for adults with positive COVID-19 tests who had “at least one risk factor for developing severe illness.” The conditional authorization was based on an analysis of phase-three trials that found that use of the antiviral COVID-19 pill drastically reduced hospitalization in people who were administered molnupiravir.

LONDON (AP) — Britain has granted a conditional authorization to Merck's coronavirus antiviral, the first pill shown to successfully treat COVID-19. It is the first country to OK the treatment, although it was not immediately clear how quickly the pill would be available. The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease. The drug, known as molnupiravir, is intended to be taken twice a day for five days by people at home with mild to moderate COVID-19....

Cervical cancer has been virtually eradicated in young women because of the HPV vaccine's 'remarkable' success, a major study has found. Cases of the disease have plummeted by 87 per cent as a result of the NHS vaccine programme. Among women now in their twenties — the first generation to get the jab — cases have now dropped from about 50 per year to just five. Today's 'historic' findings by King's College London represent the first evidence the HPV vaccine is saving lives in the UK. The HPV vaccine prevents infection from human papillomavirus, a common group of viruses that...

Editor’s Commentary: Before we get to Dr. Joseph Mercola’s article below, I thought I would offer my two conspiratorial cents on what’s driving Molnupiravir to be released instead of Ivermectin against Covid-19. First and foremost, I do not believe it is as effective as Ivermectin, and that’s the point. They don’t want an effective treatment to hamper their universal vaccination agenda, so by approving Molnupiravir instead of Ivermectin, they’re maintaining their push.This is not based on any science as I know nothing about the composition of either drug. The science is discussed below by smarter people than me. My theory...

Reuters reports October 1, 2021 Merck pill seen as ‘a huge advance’, raises hope of preventing COVID-19 deaths. Excerpts in italics with my bolds.Co will seek U.S. approval for pill as soon as possibleIf approved, would be 1st oral antiviral COVID-19 drugMerck shares rally, some vaccine makers fallU.S govt agreed to buy 1.7 mln courses at $700 eachAn antiviral pill developed by U.S. drugmaker Merck & Co (MRK.N) could half the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, with experts hailing it as a potential breakthrough in how the virus is treated.If...

Some social media users have been saying that Merck’s experimental COVID-19 antiviral product molnupiravir is a rebranded version of the anti-parasitic Ivermectin. Two disease experts have told Reuters that this is not the case and that the chemical make-up of the two drugs is different. One tweet (here ) reads, “Ivermectin is a safe cure that was removed from CDC treatment protocol. Merck refurbishes it and *poof, it’s a miracle pill. Further proof that Big Pharma is in the business of creating customers.” Similar posts on Facebook are visible here and here .One reads, in part, “The pharmaceutical giant Merck...

Biden spends over $2.4 billion on Merck wonder drug so good it deserves a 4,000% markup =========================================================================== Yesterday the pharmaceutical giant Merck asked the Food and Drug Administration to grant emergency use authorization for its new pill, Malnupiravir, that can treat COVID-19 for the eye watering price of $712, and Joe Biden already bought 1.7 million. The drug costs Merck $17.74 to produce. “Merck said it is asking for authorization for the capsules to treat infected adults who are at risk of progressing to severe Covid-19 disease or hospitalization,” reported CNN. A drug trial for Malnupiravir was reportedly ended early...

Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.If authorization is granted, the drug, made by Merck and Ridgeback Biotherapeutics, would be the first oral antiviral treatment to fight Covid-19. It comes in capsule form. Merck said it is asking for authorization for the capsules to treat infected adults who are at risk of progressing to severe Covid-19 disease or hospitalization. Its submission is based on a study that was stopped at the interim point because the drug was working so well in more than 700 patients randomly...

This is beyond disturbing. According to Dr Pierre Kory, MD, MPA, and verified by the Front Line COVID-19 Critical Care Alliance (FLCCC), 100 to 200 congressional reps and/or staff and families who contracted COVID-19 were treated with the Front Line Ivermectin protocol. ... This successful treatment is happening at the same time many congressional representatives are playing politics in favor of the vaccine; downplaying the effective anti-viral treatment and therapeutic approach with Ivermectin; and taking action to block regular American citizens from seeking similar treatment with Ivermectin. Congress can seek treatment with a medication they simultaneously deny to others? This...

Pharma giant Merck is facing accusations of price gouging after it charged the U.S. more than $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce. he New Jersey-based pharmaceutical giant Merck is facing accusations of price gouging after it charged the U.S. over $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce. Last week, Merck announced plans to request emergency federal authorization for molnupiravir after a late-stage clinical trial showed that a five-day course of the antiviral drug cut the risk of COVID-19 hospitalization...

As it turns out, all the scientists and doctors who insisted that Merck's "revolutionary" COVID drug molnupiravir is extremely safe weren't faithfully adhering to "the science" after all. Because according to a report published Thursday by Barron's, some scientists are worried that the drug - which purportedly cut hospitalizations in half during a study that was cut short - could cause cancer or birth defects.So much for having a "strong safety profile," as Dr. Scott Gottlieb claimed in an interview on the day Merck first publicized the research.It's perfectly understandable why Merck might choose to play down this safety risk:...

Bengaluru: Two drugmakers in the country have requested permission to end their late-stage trials on Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients. The two drugmakers, Aurobindo Pharma Ltd and MSN Laboratories plan to continue late-stage trails of the drug for those with mild COVID-19, the drug regulator's expert committee said on Friday. The two companies separately sought permission to end trials in the case of moderate COVID-19 patients after having submitted interim clinical trial data around the effectiveness of the drug in treating this category of patients, the committee disclosed, throwing into question the efficacy of...

Merck would turn their back on their creation with three lies about Ivermectin before they would accept the payoff from the United States government. On February 4, 2021, Merck, the corporation behind the monumental Mectizan Program, which rescued the world from River Blindness, told three untruths about Ivermectin. https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/ Lie #1: No scientific basis for a potential therapeutic effect against COVID-19 from preclinical studies; FALSE: https://www.sciencedirect.com/science/article/pii/S0166354220302011 Lie #2: No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease. FALSE: https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-Alliance-Response-to-the-NIH-Guideline-Committee-Recommendation-on-Ivermectin-use-in-COVID19-2021-01-18.pdf https://covid19criticalcare.com/wp-content/uploads/2020/12/One-Page-Summary-of-the-Clinical-Trials-Evidence-for-Ivermectin-in-COVID-19.pdf Lie #3: A concerning lack of safety data in the majority of studies. FALSE: https://committees.parliament.uk/writtenevidence/36858/pdf/

Merck’s new COVID-19 pill, known as molnupiravir, headed for FDA review for emergency authorization, could potentially carry serious safety issues stemming from the method used to kill the virus, scientists warned, according to a report. The oral antiviral medication integrates into the genetic makeup of the virus, causing a large number of mutations to destroy the virus. However, some laboratory tests indicated the drug’s ability to cause mutations in genetic material of mammalian cells, theoretically causing cancer or birth defects, Barron’s reported.

Merck's new 'not Ivermectin' Covid-19 treatment, molnupiravir, costs $17.74 to produce - yet the company is charging the US government $712 for the treatment - a 40x markup, according to The Intercept, citing a report issued last week by the Harvard School of Public Health and King’s College Hospital in London.Molnupiravir pill from Merck. Photo: Merck Sharp & Dohme Corp.The pill, originally developed using US government funds as a possible treatment for Venezuelan equine encephalitis, cut the risk of hospitalization and death in half in a randomized trial of 775 adults with mild/moderate Covid who were considered at high risk...

Shares of Merck & Co surged on positive clinical trial results of its experimental antiviral COVID-19 pill while high-flying stocks of vaccine companies and makers of other coronavirus therapies were bruised.Merck shares jumped as much as 12.3 percent and hit their highest level since February 2020 after data showed the company’s pill molnupiravir could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19.Meanwhile, shares of vaccine makers such as Moderna Inc, Pfizer Inc, and partner BioNTech SE crumbled. Moderna shares fell 13 percent in midday trading, while Pfizer, which is developing a...

Anthony Fauci, the government's top infectious diseases expert, on Friday called new trial results for a Merck pill to treat COVID-19 "impressive," as experts say the treatment could be a key tool in the pandemic fight. "The data are impressive," Fauci said at a White House press briefing, noting he was briefed by the company on its results on Thursday night. Merck said in a press release that the trial found that its drug cut the risk of hospitalization or death by 50 percent. Eight trial participants who received a placebo died, compared to zero who received the drug from...

At the start of the pandemic, researchers began testing existing antivirals in people hospitalized with severe Covid-19. But many of those trials failed to show any benefit from the antivirals. In hindsight, the choice to work in hospitals was a mistake. Scientists now know that the best time to try to block the coronavirus is in the first few days of the disease, when the virus is replicating rapidly and the immune system has not yet mounted a defense. In a trial of hospitalized patients, however, molnupiravir seemed to have no effect on the disease. In April, the companies announced...

VIDEOYup! Liberals are in heavy hype mode for the "new" LUCRATIVE Merck Covid Pill. Remember, they are only concerned about you, The People... and their stock portfolios.

Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19. If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, could be the first oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide." The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with...